Alpha 2.0
Login Register
» Articles » PMID: 33456169

Dermatomyositis, Pembrolizumab, and Squamous Cell Carcinoma of the Lung

Overview
Journal Proc (Bayl Univ Med Cent)
Specialty General Medicine
Date 2021 Jan 18
PMID 33456169
Citations 3
Authors
Claire J Wiggins
Susan Y Chon
Affiliations
Soon will be listed here.
Abstract

Cancer immunotherapy has impacted the treatment of numerous tumor types, including skin, lung, and colon cancers. Immune checkpoint inhibitors (ICI) activate the immune system to attack cancer cells, but this mechanism can also impact healthy cells. Dermatomyositis, an autoimmune syndrome affecting multiple organ systems, is often associated with cancer as a paraneoplastic syndrome, but this syndrome can also be induced by ICI. Here, we describe a case of dermatomyositis in a patient receiving pembrolizumab for treatment of squamous cell carcinoma of the lung and discuss the importance of recognizing complications of ICI.

Citing Articles

Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.

Guerra N, Matas-Garcia A, Serra-Garcia L, Morgado-Carrasco D, Padrosa J, Aldecoa I Autoimmun Rev. 2023; 22(8):103375.

PMID: 37321468 PMC: 10529928. DOI: 10.1016/j.autrev.2023.103375.

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience.

Shalata W, Zolnoorian J, Meirovitz A, Sheva K, Abu Jama A, Abu Saleh O Life (Basel). 2023; 13(1).

PMID: 36675990 PMC: 9861216. DOI: 10.3390/life13010040.

Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.

Hamada N, Maeda A, Takase-Minegishi K, Kirino Y, Sugiyama Y, Namkoong H Front Immunol. 2021; 12:803410.

PMID: 34938300 PMC: 8686164. DOI: 10.3389/fimmu.2021.803410.

References
1.
Rapoport B, van Eeden R, Sibaud V, Epstein J, Klastersky J, Aapro M . Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017; 25(10):3017-3030. DOI: 10.1007/s00520-017-3802-9. View
2.
Hinogami H, Yamashita C, Tanaka A, Shirai H, Nakano Y, Matsuura Y . Case of dermatomyositis during treatment with pembrolizumab for lung cancer. J Dermatol. 2019; 46(11):e430-e432. DOI: 10.1111/1346-8138.14993. View
3.
Curry J, Tetzlaff M, Nagarajan P, Drucker C, Diab A, Hymes S . Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2016; 44(2):158-176. DOI: 10.1111/cup.12858. View
4.
Ali S, Goddard A, Luke J, Donahue H, Todd D, Werchniak A . Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2014; 151(2):195-9. DOI: 10.1001/jamadermatol.2014.2233. View
5.
Plachouri K, Vryzaki E, Georgiou S . Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. Curr Drug Saf. 2018; 14(1):14-20. DOI: 10.2174/1574886313666180730114309. View